Immunogenicity and Safety of Different Vaccination Schedules of Tetravalent Dengue Vaccine in Healthy Subjects 9 to 50 Years of Age

NCT02628444 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

1050

Enrollment

INDUSTRY

Sponsor class

Conditions

Dengue Fever
Dengue Hemorrhagic Fever

Interventions

BIOLOGICAL: CYD Dengue Vaccine
BIOLOGICAL: Placebo (Sodium chloride 0.9%)

Sponsor

Sanofi Pasteur, a Sanofi Company